MEDI-528, now recognized as enokizumab , represents a novel therapeutic targeting the IGF-1R , a vital protein linked in various skin ailments. Early clinical data suggest significant promise for the https://teganomuw677312.aboutyoublog.com/52397174/enokizumab-a-deep-dive-into-medi-528-and-its-potential